RxDoctor Payments Data

Rinku Shrivastava, MD

Family Medicine · Castro Valley, CANPI 1225369119

Payments from drug & device makers

$3,171in general payments, 2019–2025

Across 137 payments — averaging $23.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$632
  • AstraZeneca$422
  • Lilly USA, LLC$386
  • Bayer$354
  • Boehringer Ingelheim$295
  • Pfizer$180
  • plus $902 from 12 others

What the payments were for

  • Food & beverage$3,156100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,171 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$207,000
Medicare patients
210
Services billed
2,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$67,902
JardianceEmpagliflozin30$43,891
RybelsusSemaglutide18$43,176
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$29,997
EliquisApixaban27$24,833
FarxigaDapagliflozin Propanediol21$22,069
JanuviaSitagliptin Phosphate13$18,028
Spiriva HandihalerTiotropium Bromide18$16,645
XareltoRivaroxaban11$15,746
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,788
Spiriva RespimatTiotropium Bromide11$5,816
Atorvastatin Calcium349$3,432
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,938
Levothyroxine Sodium186$2,795
Wixela InhubFluticasone Propion/Salmeterol18$2,514

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$632$111,07866 claims
Boehringer IngelheimJardiance, Spiriva Respimat$295$49,70741 claims
GSKTrelegy Ellipta$163$29,99723 claims
AstraZenecaFarxiga, Breztri Aerosphere$422$29,85733 claims
PfizerEliquis$180$24,83327 claims
MerckJanuvia$116$18,02813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Castro Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →